[go: up one dir, main page]

SG11201805592RA - Methods of producing patient-specific anti-cancer therapeutics and methods of treatment therefor - Google Patents

Methods of producing patient-specific anti-cancer therapeutics and methods of treatment therefor

Info

Publication number
SG11201805592RA
SG11201805592RA SG11201805592RA SG11201805592RA SG11201805592RA SG 11201805592R A SG11201805592R A SG 11201805592RA SG 11201805592R A SG11201805592R A SG 11201805592RA SG 11201805592R A SG11201805592R A SG 11201805592RA SG 11201805592R A SG11201805592R A SG 11201805592RA
Authority
SG
Singapore
Prior art keywords
emeryville
suite
california
street
horton
Prior art date
Application number
SG11201805592RA
Inventor
Kevin T Chapman
Mark P White
Xiaohua Wang
Minha Park
Guido K Stadler
Lowe, Jr
Radstrom Xiao Guan
Jason M Mcewen
Gang Wang
George L Fox
Peggy A Radel
Original Assignee
Berkeley Lights Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berkeley Lights Inc filed Critical Berkeley Lights Inc
Publication of SG11201805592RA publication Critical patent/SG11201805592RA/en

Links

Classifications

    • G01N33/575—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/502761—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip specially adapted for handling suspended solids or molecules independently from the bulk fluid flow, e.g. for trapping or sorting beads, for physically stretching molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/06—Fluid handling related problems
    • B01L2200/0647—Handling flowable solids, e.g. microscopic beads, cells, particles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/06—Fluid handling related problems
    • B01L2200/0647—Handling flowable solids, e.g. microscopic beads, cells, particles
    • B01L2200/0652—Sorting or classification of particles or molecules
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0809—Geometry, shape and general structure rectangular shaped
    • B01L2300/0819—Microarrays; Biochips
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Clinical Laboratory Science (AREA)
  • Fluid Mechanics (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization MD 1111101110101011111 HO 11111 0111011101110011110111 10111110H III International Bureau 0.. .... .. ..... ..or:;„, (10) International Publication Number (43) International Publication Date WO 2017/123978 Al 20 July 2017 (20.07.2017) WIPO I PCT (51) International Patent Classification: [CN/US]; 5858 Horton Street, Suite 320, Emeryville, Cali- C07K16/00 (2006.01) C07K 16/30 (2006.01) fornia 94608 (US). FOX, George L. [US/US]; 5858 Hor- C07K 16/28 (2006.01) G01N 33/569 (2006.01) ton Street, Suite 320, Emeryville, California 94608 (US). RADEL, Peggy A. [US/US]; 5858 Horton Street, Suite (21) International Application Number: 320, Emeryville, California 94608 (US). PCT/US2017/013483 (74) Agents: MCNEILL, Rebecca M. et al.; McNeill Baur (22) International Filing Date: PLLC, 125 Cambridge Park Drive, Suite 301, Cambridge, 13 January 2017 (13.01.2017) Massachusetts 02140 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (30) Priority Data: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, 62/279,341 15 January 2016 (15.01.2016) US DO, DZ, EC, EE, EG, ES, FE GB, GD, GE, GH, GM, GT, 62/411,690 23 October 2016 (23.10.2016) US HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, 62/412,092 24 October 2016 (24.10.2016) US KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (71) Applicant: BERKELEY LIGHTS, INC. [US/US]; 5858 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, Horton Street, Suite 320, Emeryville, California 94608 NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (US). RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (72) Inventors; and ZA, ZM, ZW. (71) Applicants : CHAPMAN, Kevin T. [US/US]; 5858 Hor- - ton Street, Suite 320, Emeryville, California 94608 (US). (84) Designated States (unless otherwise indicated, for every _ kind ARIPO (BW, GH, WHITE, Mark P. [US/US]; 5858 Horton Street, Suite of regional protection available): GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 320, Emeryville, California 94608 (US). WANG, Xiaohua = 5858 Horton Street, Suite 320, Emeryville, Cali- TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, [CN/US]; fornia 94608 (US). PARK, Minha [US/US]; 5858 Horton TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FE FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, = Street, Suite 320, Emeryville, California 94608 (US). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, STADLER, Guido K. [AT/US]; 5858 Horton Street, Emeryville, California 94608 (US). LOWE, JR., Randall SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, = D. 5858 Horton Street, Suite 320, Emeryville, GW, KM, ML, MR, NE, SN, TD, TG). [US/US]; = California 94608 (US). GUAN, Xiao [CN/US]; 5858 Hor- Published: = ton Street, Suite 320, Emeryville, California 94608 (US). with international search report (Art. 21(3)) — MCEWEN, Jason M. [US/US]; 5858 Horton Street, Suite 320, Emeryville, California 94608 (US). WANG, Gang, F. = = = = = = = 1-1 GC IN C :N (54) Title: METHODS OF PRODUCING PATIENT-SPECIFIC ANTI-CANCER THERAPEUTICS AND METHODS OF TREAT- en el MENT THEREFOR 1-1 ---- (57) : A method of preparing an antibody therapeutic is provided comprising: (a) providing a dissociated cell sample from IN at least one solid tumor sample obtained from a patient; (b) loading the dissociated cell sample into a microfluidic device having a C flow region and at least one isolation region fluidically connected to the flow region; (c) moving at least one B cell from the dissoci - el ated cell sample into at least one isolation region in the microfluidic device, thereby obtaining at least one isolated B cell; and (d) us - , ing the microfluidic device to identify at least one B cell that produces antibodies capable of binding to cancer cells. The cancer cells ,71 . 9 can be the patient's own cancer cells. Also provided are methods of treating patients, methods of labeling or detecting cancer, engin - .,. eered T or NK cells comprising antibodies or fragments thereof, and engineered antibody constructs.
SG11201805592RA 2016-01-15 2017-01-13 Methods of producing patient-specific anti-cancer therapeutics and methods of treatment therefor SG11201805592RA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662279341P 2016-01-15 2016-01-15
US201662411690P 2016-10-23 2016-10-23
US201662412092P 2016-10-24 2016-10-24
PCT/US2017/013483 WO2017123978A1 (en) 2016-01-15 2017-01-13 Methods of producing patient-specific anti-cancer therapeutics and methods of treatment therefor

Publications (1)

Publication Number Publication Date
SG11201805592RA true SG11201805592RA (en) 2018-07-30

Family

ID=57960827

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201805592RA SG11201805592RA (en) 2016-01-15 2017-01-13 Methods of producing patient-specific anti-cancer therapeutics and methods of treatment therefor

Country Status (10)

Country Link
US (2) US10712344B2 (en)
EP (2) EP3889176A1 (en)
JP (3) JP6902548B2 (en)
KR (1) KR102512608B1 (en)
CN (1) CN109952313B (en)
AU (2) AU2017207450B2 (en)
CA (1) CA3011087A1 (en)
SG (1) SG11201805592RA (en)
TW (2) TWI821913B (en)
WO (1) WO2017123978A1 (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE491022T1 (en) 2005-10-18 2010-12-15 Nat Jewish Health CONDITIONALLY IMMORTALIZED ADULT LONG-TERM STEM CELLS AND METHOD FOR THE PRODUCTION AND USE OF SUCH CELLS
EP2285832B1 (en) 2008-05-16 2020-08-26 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
ES2879225T3 (en) 2008-08-28 2021-11-22 Taiga Biotechnologies Inc MYC modulators, methods of using them, and methods to identify agents that modulate MYC
US8535241B2 (en) 2011-10-13 2013-09-17 Magnolia Medical Technologies, Inc. Fluid diversion mechanism for bodily-fluid sampling
US9060724B2 (en) 2012-05-30 2015-06-23 Magnolia Medical Technologies, Inc. Fluid diversion mechanism for bodily-fluid sampling
US9022950B2 (en) 2012-05-30 2015-05-05 Magnolia Medical Technologies, Inc. Fluid diversion mechanism for bodily-fluid sampling
EP2877189B1 (en) 2012-07-20 2021-01-06 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US9204864B2 (en) 2012-08-01 2015-12-08 Magnolia Medical Technologies, Inc. Fluid diversion mechanism for bodily-fluid sampling
WO2014058945A1 (en) 2012-10-11 2014-04-17 Bullington Gregory J Systems and methods for delivering a fluid to a patient with reduced contamination
WO2014085800A1 (en) 2012-11-30 2014-06-05 Magnolia Medical Technologies, Inc. Syringe based fluid diversion mechanism for bodily-fluid sampling
US10772548B2 (en) 2012-12-04 2020-09-15 Magnolia Medical Technologies, Inc. Sterile bodily-fluid collection device and methods
EP2928375B1 (en) 2012-12-04 2018-01-31 Magnolia Medical Technologies, Inc. Sterile bodily-fluid collection device
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
CN112401882B (en) 2015-09-03 2024-08-27 木兰医药技术股份有限公司 Apparatus and method for maintaining sterility of sample containers
WO2017117521A1 (en) 2015-12-31 2017-07-06 Berkeley Lights, Inc. Tumor infilitrating cells engineered to express a pro-inflammatory polypeptide
SG11201805592RA (en) 2016-01-15 2018-07-30 Berkeley Lights Inc Methods of producing patient-specific anti-cancer therapeutics and methods of treatment therefor
WO2017160991A1 (en) 2016-03-16 2017-09-21 Lavieu Gregory G Methods, systems and devices for selection and generation of genome edited clones
US11549099B2 (en) * 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
AU2017367730A1 (en) 2016-12-02 2019-06-06 Taiga Biotechnologies, Inc. Nanoparticle formulations
EP3551745A4 (en) 2016-12-12 2020-07-15 Xcella Biosciences, Inc. METHODS AND SYSTEMS FOR SCREENING USING MICROCAPILLAR ARRAYS
CN110382439A (en) 2016-12-30 2019-10-25 埃克切拉生物科学公司 Multistage sample retrieval system
EP3562594A4 (en) 2016-12-30 2020-09-09 The Regents of University of California METHOD OF SELECTION AND GENERATION OF GENOMEDITED T-CELLS
KR102264614B1 (en) 2017-04-23 2021-06-14 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. particle separation
EP3635112A2 (en) 2017-06-06 2020-04-15 Zymergen, Inc. A htp genomic engineering platform for improving fungal strains
EP4534203A3 (en) 2017-06-09 2025-05-21 Magnolia Medical Technologies, Inc. Fluid control devices and methods of using the same
EP4026554A1 (en) * 2017-08-03 2022-07-13 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
CN111212597B (en) 2017-09-12 2023-04-11 木兰医药技术股份有限公司 Fluid control device and method of use
US11041797B2 (en) 2017-12-23 2021-06-22 Lumacyte, LLC Microfluidic chip device for optical force measurements and cell imaging using microfluidic chip configuration and dynamics
US10871440B2 (en) 2017-12-23 2020-12-22 Lumacyte, LLC Microfluidic chip device for optical force measurements and cell imaging using microfluidic chip configuration and dynamics
SG11202011180UA (en) * 2018-05-31 2020-12-30 Berkeley Lights Inc Automated detection and characterization of micro-objects in microfluidic devices
WO2019236848A1 (en) 2018-06-06 2019-12-12 Zymergen Inc. Manipulation of genes involved in signal transduction to control fungal morphology during fermentation and production
CA3115808A1 (en) 2018-10-11 2020-04-16 Berkeley Lights, Inc. Systems and methods for identification of optimized protein production and kits therefor
US12318775B2 (en) 2018-12-06 2025-06-03 xCella Biosciences, Inc. Lateral loading of microcapillary arrays
AU2020234829B2 (en) 2019-03-11 2025-11-13 Magnolia Medical Technologies, Inc. Fluid control devices and methods of using the same
TWI901456B (en) * 2019-03-19 2025-10-11 美商路瑪賽特股份有限公司 Microfluidic device for optical force measurements, cell imaging, and assessing biological particles and the method using the same
TWI866902B (en) * 2019-03-19 2024-12-21 美商路瑪賽特有限責任公司 Microfluidic device for optical force measurements, cell imaging, and assessing biological particles and the method using the same
JP2022527117A (en) 2019-04-08 2022-05-30 タイガ バイオテクノロジーズ，インク． Compositions and Methods for Cryopreservation of Immune Cells
CN111808815A (en) * 2019-04-11 2020-10-23 北京基石生命科技有限公司 Method for culturing primary cells of gastric cancer solid tumor
WO2020232141A2 (en) 2019-05-14 2020-11-19 Taiga Biotechnologies, Inc. Compositions and methods for treating t cell exhaustion
WO2020233503A1 (en) * 2019-05-17 2020-11-26 University Of Macau Detection method
JP2022535922A (en) 2019-06-25 2022-08-10 ヒューレット－パッカード デベロップメント カンパニー エル．ピー． Molded structure with channels
US11335636B2 (en) * 2019-10-29 2022-05-17 Hefei Reliance Memory Limited Gradual breakdown memory cell having multiple different dielectrics
CA3158045A1 (en) * 2019-11-21 2021-05-27 Emulate Inc. Antibody producing microfluidic devices
WO2022004620A1 (en) * 2020-06-29 2022-01-06 株式会社Npt Method for manufacturing composition including antigen-specific antibody-producing cells, method for manufacturing vaccine composition, cell separation kit, and vaccine composition
JP7197538B2 (en) * 2020-07-03 2022-12-27 タイガ バイオテクノロジーズ，インク． Methods and compositions for treating melanoma
US11479779B2 (en) 2020-07-31 2022-10-25 Zymergen Inc. Systems and methods for high-throughput automated strain generation for non-sporulating fungi
US20220304664A1 (en) * 2021-03-26 2022-09-29 Jeremy Hammer Apparatus and methods for bodily fluid sample collection
US11763647B2 (en) * 2021-08-16 2023-09-19 City University Of Hong Kong Multimode haptic patch and multimodal haptic feedback interface
CN113996355B (en) * 2021-10-28 2023-06-06 上海浚真生命科学有限公司 Sampling device
US12252678B2 (en) 2021-12-01 2025-03-18 Microfluidx Ltd Systems and methods for bioprocessing
CN118556076A (en) * 2022-01-17 2024-08-27 深圳华大生命科学研究院 Method for obtaining information of nano-antibodies that specifically recognize antigens
CN114574587B (en) * 2022-04-06 2022-12-02 北京莱盟君泰国际医疗技术开发有限公司 Marker composition for colorectal cancer detection and application thereof
CN115746120B (en) * 2022-05-26 2025-11-18 浙江省人民医院 Human IGF2BP3 protein, antibody and its application
WO2024250037A1 (en) * 2023-06-02 2024-12-05 Northeastern University Targeted immune cell therapy utilizing trail and tnf mediated apoptosis
US20250216378A1 (en) * 2023-12-28 2025-07-03 Biobridge Global Methods for performing miniaturized dynamic assays using microfluidics and related systems

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2618497B2 (en) * 1989-10-03 1997-06-11 鐘淵化学工業株式会社 Tumor-damaging cell inducer and tumor-damaging cell induction device
ES2288760T3 (en) 1996-04-25 2008-01-16 Bioarray Solutions Ltd. ELECTROCINETIC ASSEMBLY CONTROLLED BY LIGHT OF PARTICLES NEXT TO SURFACES.
US6294063B1 (en) 1999-02-12 2001-09-25 Board Of Regents, The University Of Texas System Method and apparatus for programmable fluidic processing
US6942776B2 (en) 1999-05-18 2005-09-13 Silicon Biosystems S.R.L. Method and apparatus for the manipulation of particles by means of dielectrophoresis
US7223364B1 (en) 1999-07-07 2007-05-29 3M Innovative Properties Company Detection article having fluid control film
ATE304174T1 (en) * 2000-06-14 2005-09-15 Univ Texas SYSTEMS AND METHODS FOR CELL PART POPULATION ANALYSIS
US20030007894A1 (en) 2001-04-27 2003-01-09 Genoptix Methods and apparatus for use of optical forces for identification, characterization and/or sorting of particles
ITTO20010411A1 (en) 2001-05-02 2002-11-02 Silicon Biosystems S R L METHOD AND DEVICE FOR THE EXECUTION OF TESTS AND TESTS WITH HIGH PROCESSIVITY AND HIGH BIOLOGICAL VALUE ON CELLS AND / OR COMPOUNDS.
US7312085B2 (en) 2002-04-01 2007-12-25 Fluidigm Corporation Microfluidic particle-analysis systems
US6958132B2 (en) 2002-05-31 2005-10-25 The Regents Of The University Of California Systems and methods for optical actuation of microfluidics based on opto-electrowetting
US7790443B2 (en) 2002-08-27 2010-09-07 Vanderbilt University Bioreactors with substance injection capacity
EP1561107A1 (en) * 2002-11-13 2005-08-10 Micromet AG Method for identifying antigen specific b cells
WO2004065618A2 (en) 2003-01-16 2004-08-05 Thermogenic Imaging Methods and devices for monitoring cellular metabolism in microfluidic cell-retaining chambers
EP2340890B1 (en) 2003-04-03 2016-10-19 Fluidigm Corporation Method of performimg digital PCR
JP4328168B2 (en) 2003-10-02 2009-09-09 ソニー株式会社 Detection unit for interaction between substances using capillary phenomenon, method using the detection unit, and substrate for bioassay
WO2005053729A1 (en) 2003-11-26 2005-06-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Stem cell factor for inducing neural stem cell migration to areas of neurological injury
US7425253B2 (en) 2004-01-29 2008-09-16 Massachusetts Institute Of Technology Microscale sorting cytometer
US8765454B2 (en) 2004-02-18 2014-07-01 Xiaochuan Zhou Fluidic devices and methods for multiplex chemical and biochemical reactions
EP1735428A4 (en) 2004-04-12 2010-11-10 Univ California OPTOELECTRONIC CLAMPS FOR HANDLING MICROPARTICLES AND CELLS
US20060091015A1 (en) 2004-11-01 2006-05-04 Applera Corporation Surface modification for non-specific adsorption of biological material
US9260688B2 (en) 2005-07-07 2016-02-16 The Regents Of The University Of California Methods and apparatus for cell culture array
EP1915467A2 (en) 2005-08-19 2008-04-30 The Regents of the University of California Microfluidic methods for diagnostics and cellular analysis
US8449837B2 (en) 2005-10-11 2013-05-28 The Johns Hopkins University Microfluidic device for high-throughput cellular gradient and dose response studies
WO2007102839A2 (en) 2005-10-27 2007-09-13 Applera Corporation Optoelectronic separation of biomolecules
WO2007092713A2 (en) * 2006-02-02 2007-08-16 Trustees Of The University Of Pennsylvania Microfluidic system and method for analysis of gene expression in cell-containing samples and detection of disease
US8124015B2 (en) 2006-02-03 2012-02-28 Institute For Systems Biology Multiplexed, microfluidic molecular assay device and assay method
KR101667981B1 (en) * 2006-12-28 2016-10-20 얀센 바이오테크 인코포레이티드 Methods and vectors for generating asialylated immunoglobulins
EP2125219B1 (en) 2007-01-19 2016-08-10 Fluidigm Corporation High precision microfluidic devices and methods
WO2008091848A2 (en) 2007-01-22 2008-07-31 Advanced Liquid Logic, Inc. Surface assisted fluid loading and droplet dispensing
WO2008119066A1 (en) 2007-03-28 2008-10-02 The Regents Of The University Of California Single-sided lateral-field and phototransistor-based optoelectronic tweezers
US20080302732A1 (en) 2007-05-24 2008-12-11 Hyongsok Soh Integrated fluidics devices with magnetic sorting
WO2009011808A1 (en) 2007-07-13 2009-01-22 President And Fellows Of Harvard College Droplet-based selection
CA2705213C (en) 2007-11-07 2016-10-04 The University Of British Columbia Microfluidic device and method of using same
US20100086919A1 (en) * 2008-04-11 2010-04-08 China Molecular, Ltd. Devices and methods for immunoglobulin production
US20110117634A1 (en) 2008-04-21 2011-05-19 Asaf Halamish Flat cell carriers with cell traps
CN101275114A (en) 2008-04-22 2008-10-01 北京大学 A microfluidic cell culture array and its application
GB2464300A (en) 2008-10-10 2010-04-14 Univ Dublin City Microfluidic multiplexed cellular and molecular analysis device and method
US20110236393A1 (en) * 2008-11-04 2011-09-29 Duke University Monoclonal antibody production in b cells and uses therof
US20120045827A1 (en) 2009-03-09 2012-02-23 Biofactura, Inc. Separation of antigen-specific memory b cells with a conjugated biopolymer surface
JP2012522518A (en) 2009-04-03 2012-09-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Method and apparatus for sorting cells and bioparticles
US20100273681A1 (en) 2009-04-27 2010-10-28 Wisconsin Alumni Research Foundation Combinatorial chemistry reaction cell with optical tweezers
GB0909923D0 (en) 2009-06-09 2009-07-22 Oxford Gene Tech Ip Ltd Picowell capture devices for analysing single cells or other particles
JP2011000079A (en) 2009-06-19 2011-01-06 Univ Of Tokyo Method for operating particle and micro fluid device
KR20130009760A (en) 2010-02-10 2013-01-23 이뮤노젠 아이엔씨 Cd20 antibodies and uses thereof
JPWO2011149032A1 (en) 2010-05-26 2013-07-25 東ソー株式会社 Biological sample fixing device
CN101947124B (en) 2010-06-25 2012-07-04 博奥生物有限公司 Integrated microfluidic chip device and using method thereof
US10087408B2 (en) 2010-07-07 2018-10-02 The University Of British Columbia System and method for microfluidic cell culture
US20130115606A1 (en) 2010-07-07 2013-05-09 The University Of British Columbia System and method for microfluidic cell culture
US9188593B2 (en) 2010-07-16 2015-11-17 The University Of British Columbia Methods for assaying cellular binding interactions
US9533306B2 (en) 2010-08-02 2017-01-03 The Regents Of The University Of California Single sided continuous optoelectrowetting (SCEOW) device for droplet manipulation with light patterns
EP2616551B1 (en) 2010-09-14 2020-08-19 The Regents of The University of California Method for isolating cells from heterogeneous solution using microfluidic trapping vortices
US9891157B2 (en) 2010-12-03 2018-02-13 Cellply S.R.L. Microanalysis of cellular function
EP2646830B1 (en) 2010-12-03 2016-04-13 Cellply S.R.L. Rapid screening of monoclonal antibodies
WO2012094642A2 (en) 2011-01-06 2012-07-12 On-Q-ity Circulating tumor cell capture on a microfluidic chip incorporating both affinity and size
KR102117921B1 (en) 2011-02-28 2020-06-03 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Cell culture system
WO2012162779A1 (en) 2011-05-27 2012-12-06 The University Of British Columbia Microfluidic cell trap and assay apparatus for high-throughput analysis
US9227200B2 (en) 2011-06-03 2016-01-05 The Regents Of The University Of California Microfluidic devices with flexible optically transparent electrodes
EP2739587B1 (en) 2011-08-01 2020-05-27 Denovo Sciences Cell capture system
US9050593B2 (en) 2011-11-23 2015-06-09 Wisconsin Alumni Research Foundation Self-loading microfluidic device and methods of use
WO2013107907A1 (en) * 2012-01-20 2013-07-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for the prognosis of survival time of a patient suffering from a solid cancer
US20150246335A1 (en) 2012-09-13 2015-09-03 President And Fellows Of Harvard College Methods for multiplex analytical measurements in single cells of solid tissues
US9857333B2 (en) 2012-10-31 2018-01-02 Berkeley Lights, Inc. Pens for biological micro-objects
US9403172B2 (en) 2012-11-08 2016-08-02 Berkeley Lights, Inc. Circuit based optoelectronic tweezers
CN105492621A (en) 2013-03-28 2016-04-13 英属哥伦比亚大学 Microfluidic devices and methods of their use in multicellular secretion assays
CA3095333C (en) * 2013-10-22 2024-01-30 Berkeley Lights, Inc. Microfluidic devices having sequestration pens and methods of testing biological micro-objects with same
SG10202002543UA (en) 2013-10-22 2020-05-28 Berkeley Lights Inc Micro-fluidic devices for assaying biological activity
US9889445B2 (en) 2013-10-22 2018-02-13 Berkeley Lights, Inc. Micro-fluidic devices for assaying biological activity
US20150306599A1 (en) 2014-04-25 2015-10-29 Berkeley Lights, Inc. Providing DEP Manipulation Devices And Controllable Electrowetting Devices In The Same Microfluidic Apparatus
AU2015249294B2 (en) 2014-04-25 2020-02-27 Berkeley Lights, Inc. Providing DEP manipulation devices and controllable electrowetting devices in the same microfluidic apparatus
US20150306598A1 (en) 2014-04-25 2015-10-29 Berkeley Lights, Inc. DEP Force Control And Electrowetting Control In Different Sections Of The Same Microfluidic Apparatus
WO2015188171A1 (en) 2014-06-06 2015-12-10 Berkeley Lights, Inc. Isolating microfluidic structures and trapping bubbles
CN104293666B (en) * 2014-09-11 2016-06-22 大连理工大学 The micro flow control chip device of the interphase interaction that two kinds of differences are unicellular
EP3212757A4 (en) 2014-10-27 2018-07-04 The Governing Council of the University of Toronto Microfluidic device for cell-based assays
CA2970174C (en) 2014-12-08 2024-01-23 Berkeley Lights, Inc. Microfluidic device comprising lateral/vertical transistor structures and process of making and using same
US9744533B2 (en) 2014-12-10 2017-08-29 Berkeley Lights, Inc. Movement and selection of micro-objects in a microfluidic apparatus
US10384204B2 (en) 2014-12-10 2019-08-20 Berkeley Lights, Inc. Systems for operating electrokinetic devices
IL284235B (en) 2015-04-22 2022-07-01 Berkeley Lights Inc Kits and methods for preparing a microfluidic device for cell culture
KR20230042540A (en) 2015-12-30 2023-03-28 버클리 라잇츠, 인크. Microfluidic devices for optically-driven convection and displacement, kits and methods thereof
SG11201805592RA (en) 2016-01-15 2018-07-30 Berkeley Lights Inc Methods of producing patient-specific anti-cancer therapeutics and methods of treatment therefor
SG11201808914UA (en) 2016-04-15 2018-11-29 Berkeley Lights Inc Methods, systems and kits for in-pen assays
CN109689213B (en) 2016-05-26 2022-10-14 伯克利之光生命科技公司 Covalently modified surface, kit, preparation method and application

Also Published As

Publication number Publication date
US10712344B2 (en) 2020-07-14
US20170276679A1 (en) 2017-09-28
JP2019511454A (en) 2019-04-25
AU2022200495A1 (en) 2022-02-17
CA3011087A1 (en) 2017-07-20
EP3889176A1 (en) 2021-10-06
AU2017207450B2 (en) 2021-11-04
CN109952313A (en) 2019-06-28
TWI756199B (en) 2022-03-01
JP2023082046A (en) 2023-06-13
US11971409B2 (en) 2024-04-30
TW201734207A (en) 2017-10-01
TW202221321A (en) 2022-06-01
CN109952313B (en) 2023-12-19
WO2017123978A1 (en) 2017-07-20
KR20180101548A (en) 2018-09-12
KR102512608B1 (en) 2023-03-22
JP2021153594A (en) 2021-10-07
AU2017207450A1 (en) 2018-07-19
JP6902548B2 (en) 2021-07-14
TWI821913B (en) 2023-11-11
US20200400669A1 (en) 2020-12-24
EP3402814B1 (en) 2021-04-21
EP3402814A1 (en) 2018-11-21

Similar Documents

Publication Publication Date Title
SG11201805592RA (en) Methods of producing patient-specific anti-cancer therapeutics and methods of treatment therefor
SG11201808573YA (en) Nucleic acid stabilization reagent, kits, and methods of use thereof
SG11201910019PA (en) Microorganisms and methods for producing cannabinoids and cannabinoid derivatives
SG11201808022WA (en) Selection and cloning of t lymphocytes in a microfluidic device
SG11201910096RA (en) Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use
SG11201900885VA (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201908787WA (en) Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
SG11201908238SA (en) Anti-c5 antibodies and uses thereof
SG11201804360XA (en) Mat2a inhibitors for treating mtap null cancer
SG11201907753TA (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201900138TA (en) Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
SG11201807041PA (en) Improved preparations of adult liver progenitor cells
SG11201907299XA (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SG11201808762XA (en) Diagnostic methods for patient specific therapeutic decision making in cancer care
SG11201809005TA (en) Plasma-based detection of anaplastic lymphoma kinase (alk) nucleic acids and alk fusion transcripts and uses thereof in diagnosis and treatment of cancer
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201805268XA (en) T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201809252YA (en) Methods for determining dpp3 and therapeutic methods
SG11201907208XA (en) Radiolabeled anti-lag3 antibodies for immuno-pet imaging
SG11201903771XA (en) Binding molecules specific for asct2 and uses thereof
SG11201906778RA (en) Improved methods for assessing risk of developing breast cancer
SG11201908127WA (en) Method for producing multispecific antibodies
SG11201900329XA (en) Combination test for colorectal cancer